Uniform nano-sized valsartan for dissolution and bioavailability enhancement: Influence of particle size and crystalline state

International Journal of Pharmaceutics

Volumn 441, Issue 1-2, 2013, Pages 75-81

  Ma, Qiuping ^a   Sun, Hongrui ^a   Che, Erxi ^a   Zheng, Xin ^a   Jiang, Tongying ^a   Sun, Changshan ^a   Wang, Siling ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bioavailability; Crystalline state; Dissolution; Nanosuspension; Particle size; Valsartan

Indexed keywords

VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NANOANALYSIS; NANOSUSPENSION; NONHUMAN; PARTICLE SIZE; PH; POWDER; PRECIPITATION; PRIORITY JOURNAL; RAT; ROOM TEMPERATURE; SPRAY DRYING; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CRYSTALLIZATION; DRUG STABILITY; DRUG STORAGE; HYDROGEN-ION CONCENTRATION; MALE; MICROSPHERES; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TETRAZOLES; TIME FACTORS; VALINE;

EID: 84871989868     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.12.025     Document Type: Article

References (29)

1. A.A. Ambike, K.R. Mahadik, and A. Paradkar Spray-dried amorphous solid dispersions of simvastatin, a low tg drug: in vitro and in vivo evaluations Pharm. Res. 22 2005 990 998
2. B. Cappello, C. Di Maio, M. Iervolino, and A. Miro Improvement of solubility and stability of Valsartan by hydroxypropyl-beta-cyclodextrin J. Incl. Phenom. Macro. 54 2006 289 294
3. M.V. Chaubal, and C. Popescu Conversion of nanosuspensions into dry powders by spray drying: a case study Pharm. Res. 25 2008 2302 2308
4. M. Clark, M.A. Jepson, and B.H. Hirst Exploiting M cells for drug and vaccine delivery Adv. Drug Deliv. Rev. 50 2001 81 106
5. G.E. Downton, J.L. Flores-Luna, and C.J. Klng Mechanism of stickiness in hygroscopic, amorphous powders Ind. Eng. Chem. Fundam. 21 1982 447 451
6. G. Flesch, P. Müller, and P. Lloyd Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man Eur. J. Clin. Pharmacol. 52 1997 115 120
7. A.T. Florence, and N. Hussain Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas Adv. Drug. Deliv. Rev. 50 2001 S69 S89
8. V.M. Gun'ko, V.I. Zarko, R. Leboda, and E. Chibowski Aqueous suspension of fumed oxides: particle size distribution and zeta potential Adv. Colloid Interface Sci. 91 2001 1 112
9. B.C. Hancock, and G. Zografi Characteristics and significance of the amorphous state in pharmaceutical systems J. Pharm. Sci. 86 1997 1 12
10. Y. Hu, Z. Zhi, T. Wang, T. Jiang, and S. Wang Incorporation of indomethacin nanoparticles into 3-D ordered macroporous silica for enhanced dissolution and reduced gastric irritancy Eur. J. Pharm. Biopharm. 79 2011 544 551
11. P. Jani, G.W. Halbert, J. Langridge, and A.T. Florence Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency J. Pharm. Pharmacol. 42 1990 821 826
12. O. Kayser, C. Olbrich, V. Yardley, A.F. Kiderlen, and S.L. Croft Formulation of amphotericin B as nanosuspension for oral administration Int. J. Pharm. 254 2003 73 75
13. C. Keck, S. Kobierski, R. Mauludin, and R.H. Müller Second generation of drug nanocrystals for delivery of poorly soluble drugs: smart crystals technology Dosis 24 2008 124 128
14. C.M. Keck, and R.H. Müller Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation Eur. J. Pharm. Biopharm. 62 2006 3 16
15. D.X. Li, Y.D. Yan, D.H. Oh, K.Y. Yang, Y.G. Seo, J.O. Kim, Y.I. Kim, C.S. Yong, and H.G. Choi Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer Drug Deliv. 17 2010 322 329
16. R.H. Müller, R. Shegokar, S. Gohla, and C.M. Keck Nanocrystals: production, cellular drug delivery, current and future products Intracell. Deliv. 5 2011 411 432
17. R.H. Müller, and C.M. Keck Twenty years of drug nanocrystals: where are we, and where do we go? Eur. J. Pharm. Biopharm. 80 2012 1 3
18. Y.J. Park, H.K. Lee, Y.B. Im, W. Lee, and H.K. Han Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion Arch. Pharm. Res. 33 2010 1235 1240
19. V.B. Patravale, A.A. Date, and R.M. Kulkarni Nanosuspensions: a promising drug delivery strategy J. Pharm. Pharmacol. 56 2004 827 840
20. B.E. Rabinow Nanosuspensions in drug delivery Nat. Rev. Drug Discov. 3 2004 785 796
21. R. Shegokar, and R.H. Müller Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives Int. J. Pharm. 399 2010 129 139
22. D. Singhal, and W. Curatolo Drug polymorphism and dosage form design: a practical perspective Adv. Drug Deliv. Rev. 56 2004 335 347
23. Skotnicki, M., Gawel, A., Cebe, P., Pyda, M., 2012. Thermal behavior and phase identification of valsartan by standard and temperature-modulated differential scanning calorimetry. Drug Dev. Ind. Pharm. [Epub ahead of print].
24. B. Van Eerdenbrugh, S. Vercruysse, J.A. Martens, J. Vermant, L. Froyen, J. Van Humbeeck, G. Van den Mooter, and P. Augustijns Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions-a case study with itraconazole Eur. J. Pharm. Biopharm. 70 2008 590 596
25. B. Van Erdenbrugh, L. Froyen, J. Van Humbeeck, J.A. Martens, P. Augustijins, and G. Van Den Mooter Alternative matrix formers for nanosuspension solidification: dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion Eur. J. Pharm. Sci. 35 2008 344 353
26. S. Verma, R. Gokhale, and D.J. Burgess A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions Int. J. Pharm. 380 2009 216 222
27. Y.D. Yan, J.H. Sung, K.K. Kim, D.W. Kim, J.O. Kim, B.J. Lee, C.S. Yong, and H.G. Choi Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes Int. J. Pharm. 422 2012 202 210
28. 2: prevention of excessive agglomeration J. Supercrit. Fluids 59 2011 117 123
29. Y. Zhang, J. Wang, X. Bai, T. Jiang, Q. Zhang, and S. Wang Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs Mol. Pharm. 9 2012 505 513